PRAVASTATIN TEVA 20 MG

Negara: Israel

Bahasa: Inggris

Sumber: Ministry of Health

Bahan aktif:

PRAVASTATIN SODIUM

Tersedia dari:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Kode ATC:

C10AA03

Bentuk farmasi:

TABLETS

Komposisi:

PRAVASTATIN SODIUM 20 MG

Rute administrasi :

PER OS

Jenis Resep:

Required

Diproduksi oleh:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Kelompok Terapi:

PRAVASTATIN

Area terapi:

PRAVASTATIN

Indikasi Terapi:

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *Primary prevention of coronary events: In hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - Reduce the risk of myocardial infarcton. - Reduce the risk for revascularization. - Reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *Secondary prevention of cardiovascular events: Atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior MI Pravastatin is indicated to: - Slow the progression of coronary atherosclerosis. - Reduce the risk of acute co

Tanggal Otorisasi:

2012-01-31

Selebaran informasi

THE FORMAT OF THIS LEAFLET WAS
DETERMINED BY THE MINISTRY OF HEALTH
AND ITS CONTENT THEREOF WAS CHECKED
AND APPROVED
PATIENT PACKAGE INSERT
IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
(PREPARATIONS) - 1986
The medicine is dispensed with
a doctor’s prescription only
PRAVASTATIN TEVA
®
10 MG
TABLETS
Each tablet contains:
Pravastatin sodium 10 mg
PRAVASTATIN TEVA
®
20 MG
TABLETS
Each tablet contains:
Pravastatin sodium 20 mg
PRAVASTATIN TEVA
®
40 MG
TABLETS
Each tablet contains:
Pravastatin sodium 40 mg
For the list of inactive ingredients, please
see section 6.
READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY
BEFORE USING THE MEDICINE. This leaflet
contains concise information about the
medicine. If you have further questions,
refer to the doctor or pharmacist.
This medicine has been prescribed to treat
your ailment. Do not pass it on to others. It
may harm them even if it seems to you that
their ailment is similar.
This medicine is not intended for use in
children and adolescents under 18 years
of age.
1. WHAT IS THE MEDICINE INTENDED
FOR?
∙ Reduction of cholesterol and triglycerides
levels.
∙ Reduction of the risk of myocardial
infarction and extension of life expectancy
in hypercholesterolemic patients with no
evidence of coronary disease.
∙ Reduction of the risk of overall mortality by
lowering mortality due to heart diseases,
and reduction of the risk of heart attack in
patients with atherosclerosis and average
or high cholesterol level.
THERAPEUTIC GROUP:
From the family of statins that inhibit
the activity of the HMG-CoA reductase
enzyme.
2. BEFORE USING THE MEDICINE: WHEN THE PREPARATION SHOULD NOT BE
USED:
∙ When you are pregnant, planning
to
become
pregnant
or
are
breastfeeding.
∙ If you have a known sensitivity to any
of its ingredients (the list of inactive
ingredients is in section 6).
∙ If you are suffering from active liver
disease or from unexplained, persistent
enzyme elevations in liver function
tests.
SPECIAL WARNINGS REGARDING USE OF THE
MEDICINE:
∙ This preparation contains